ArticleJournal of the American Heart Association2026
Using a Biomarker of Biological Aging to Predict Incident Cardiometabolic Disease.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe ability to predict cardiometabolic risk is essential to support efforts to prevent future onset of disease. Biomarkers that assess biological aging-the rate of decline in physiological functioning that occurs across the systems of the human body-have the potential to support this goal.
methodsWe investigated the extent to which Dunedin Pace of Aging Calculated From the Epigenome (DunedinPACE), an epigenetic measure of biological aging, predicted cardiometabolic disease onset in a cohort of 2062 US military veterans free of disease at baseline and followed for an average of 14.1 years via electronic health records. Other clinical biomarkers included hemoglobin A1C, blood pressure, pulse, and body mass index.
resultsDunedinPACE predicted incident cardiometabolic disease onset (hazard ratio [HR]=1.82 [95% CI, 1.64-2.04];
conclusionsThese results suggest that DunedinPACE improves prediction of cardiometabolic disease compared with other clinical biomarkers and could help identify individuals who would benefit from preventative interventions that delay the onset of cardiometabolic disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.